Arcturus Therapeutics (ARCT) Projected to Post Quarterly Earnings on Monday

Arcturus Therapeutics (NASDAQ:ARCT) is expected to announce its Q1 2025 earnings results after the market closes on Monday, May 12th. Analysts expect Arcturus Therapeutics to post earnings of ($1.10) per share and revenue of $25.64 million for the quarter.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). The business had revenue of $22.77 million during the quarter, compared to analysts’ expectations of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. On average, analysts expect Arcturus Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arcturus Therapeutics Stock Down 3.5 %

Arcturus Therapeutics stock opened at $10.98 on Friday. The firm has a fifty day simple moving average of $11.87 and a two-hundred day simple moving average of $15.45. Arcturus Therapeutics has a twelve month low of $8.04 and a twelve month high of $45.00. The company has a market capitalization of $297.79 million, a PE ratio of -4.95 and a beta of 2.36.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ARCT shares. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday, April 10th. BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. Canaccord Genuity Group dropped their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, March 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Finally, Wells Fargo & Company cut their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Arcturus Therapeutics has a consensus rating of “Buy” and an average target price of $59.20.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.